Overview

Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)

Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Scientific Corporation
Treatments:
Polidocanol